PDF(Pubmed)
Abstract：
BACKGROUND: This study details a case of a patient with advanced lung adenocarcinoma harboring an exon 19 deletion in the EGFR gene.
METHODS: A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib. Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. PET-CT and CT scans were used to assess the tumor response to treatment.
RESULTS: A significant increase in total lymphocyte percentage and decrease in the number of CTCs in the patient was observed. Imaging studies showed a notable reduction in tumor metastases.
CONCLUSIONS: This report demonstrates the safety and efficacy of TSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions. This study describes a promising new treatment option for patients with advanced lung cancer with EGFR mutations.
METHODS: A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib. Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. PET-CT and CT scans were used to assess the tumor response to treatment.
RESULTS: A significant increase in total lymphocyte percentage and decrease in the number of CTCs in the patient was observed. Imaging studies showed a notable reduction in tumor metastases.
CONCLUSIONS: This report demonstrates the safety and efficacy of TSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions. This study describes a promising new treatment option for patients with advanced lung cancer with EGFR mutations.
摘要：
背景：本研究详细介绍了一例晚期肺腺癌患者的EGFR基因缺失外显子19。
方法：一名46岁女性患者被诊断为IVb期左肺腺癌，多发骨及淋巴结转移.在鉴定肿瘤特异性抗原肽后，患者接受了免疫治疗(TSA-DC-CTL)和口服奥希替尼的联合治疗.治疗前后监测外周血循环免疫细胞和循环肿瘤细胞（CTC）。PET-CT和CT扫描用于评估肿瘤对治疗的反应。
结果：观察到患者的总淋巴细胞百分比显着增加，CTC数量减少。影像学研究显示肿瘤转移明显减少。
结论：本报告证明了TSA-DC-CTL细胞免疫治疗联合奥希替尼治疗EGFR外显子19缺失的晚期肺腺癌患者的安全性和有效性。这项研究为EGFR突变的晚期肺癌患者描述了一种有希望的新治疗选择。
方法：一名46岁女性患者被诊断为IVb期左肺腺癌，多发骨及淋巴结转移.在鉴定肿瘤特异性抗原肽后，患者接受了免疫治疗(TSA-DC-CTL)和口服奥希替尼的联合治疗.治疗前后监测外周血循环免疫细胞和循环肿瘤细胞（CTC）。PET-CT和CT扫描用于评估肿瘤对治疗的反应。
结果：观察到患者的总淋巴细胞百分比显着增加，CTC数量减少。影像学研究显示肿瘤转移明显减少。
结论：本报告证明了TSA-DC-CTL细胞免疫治疗联合奥希替尼治疗EGFR外显子19缺失的晚期肺腺癌患者的安全性和有效性。这项研究为EGFR突变的晚期肺癌患者描述了一种有希望的新治疗选择。
